<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Issues related to solid organ transplantation</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Issues related to solid organ transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Issues related to solid organ transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ajit P Limaye, MD, FACP, FIDSA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karen Hardinger, PharmD, BCPS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H4221841800"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Solid organ transplant recipients may be at increased risk for coronavirus disease 2019 (COVID-19) because they are immunosuppressed and are less likely to mount effective immune responses to vaccination. </p><p>This topic reviews aspects of COVID-19 that are specific to solid organ transplantation, including screening prior to transplantation, distinct clinical features, managing immunosuppression, and important drug interactions. Other aspects of COVID-19 care are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a> and  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p class="headingAnchor" id="H2731562136"><span class="h1">RISK OF TRANSMISSION</span></p><p class="headingAnchor" id="H3345035200"><span class="h2">Potential for donor-derived infection</span><span class="headingEndMark"> — </span>Donor-derived infection has been reported with lung transplantation but not with other organs [<a href="#rid1">1</a>]. For non-lung organ transplantation, data from case series have shown that transplantation of non-lung organs from SARS-CoV-2-infected donors can be safely performed [<a href="#rid1">1-6</a>]. While data are limited, there is no evidence that non-lung organ transplantation from a SARS-CoV-2-infected donor leads to worse short-term outcomes. As an example, one single-center study of 220 deceased-donor kidney transplants found similar rates of delayed graft function, rejection, graft failure, mortality, and COVID-19 diagnoses among recipients of SARS-CoV-2-infected and SARS-CoV-2-uninfected donor kidneys at a median of 5.7 months [<a href="#rid7">7</a>].</p><p>Bloodborne transmission has not been reported and is not expected; the frequency, duration, and magnitude of SARS-CoV-2 viremia are low [<a href="#rid8">8-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7950.html" rel="external">"Blood donor screening: Medical history", section on 'Active or prior COVID-19'</a>.)</p><p class="headingAnchor" id="H3710127219"><span class="h2">Posttransplantation risk</span><span class="headingEndMark"> — </span>It is not known whether solid organ transplant recipients are at higher risk for acquiring SARS-CoV-2 infection than the general population. However, chronic immunosuppression may lower the infectious dose needed to cause infection and impair adequate immune control once infection is established.</p><p>Like other immunosuppressed persons, solid organ transplant recipients may shed greater amounts of virus for longer durations than otherwise healthy hosts. Thus, they may be more likely to spread infection to others. Further data are needed to confirm these theories and to quantify viral dynamics and the risk of transmission to others.</p><p class="headingAnchor" id="H1984046478"><span class="h1">PRETRANSPLANTATION SCREENING</span><span class="headingEndMark"> — </span>With declining rates of COVID-19 and the ending of the pandemic emergency, practices for organ donor and potential recipient screening are evolving, with some centers no longer routinely screening asymptomatic potential recipients and/or donors. It is likely that policies for donor and potential recipient screening will be tailored to COVID-19 activity, with enhanced screening at times of increased community activity.</p><p class="headingAnchor" id="H2438087673"><span class="h2">Donor screening</span><span class="headingEndMark"> — </span>All donors should be screened for SARS-CoV-2 infection [<a href="#rid12">12</a>]. We generally perform a careful history, obtain chest imaging, and perform microbiologic testing. In all cases, the decision to proceed to transplantation should consider the urgency of the transplant and the risk and benefits in each individual. General principles adapted from the American Society of Transplantation (AST) guidelines and Organ Procurement and Transplantation Network (OPTN) on SARS-CoV-2 donor evaluation and testing are below [<a href="#rid13">13,14</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Living donors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Self-quarantine for 14 days prior to donation should be considered to reduce the risk of SARS-CoV-2 infection, during times of community COVID-19 activity. At a minimum, we ask donors to avoid high-risk activities and to mask and take other general precautions prior to donation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At the time of donation, donors should be screening for symptoms and potential exposures, according to local center guidelines and policies. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Deceased donors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening should include assessing for past COVID-19, vaccination history, recent exposures, and the timing of these events relative to the donation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A nucleic acid amplification test (NAAT) for SARS-CoV-2 should be performed on nasopharyngeal samples from deceased donors within 72 hours and, ideally, as close as possible to organ recovery. When lungs are recovered for transplantation, NAAT for SARS-CoV-2 should be performed on both nasopharyngeal and lower respiratory tract samples.</p><p></p><p>Lung transplantation from donors with active infection is generally not recommended. Some centers have avoided the use of donors with active infection and death due to severe COVID-19 or donors with thrombotic complications due to COVID-19, even for non-lung organ transplantation.</p><p>For donors with resolved COVID-19 who test positive by NAAT, the decision to proceed to transplantation should be on a case-by-case basis and consider the urgency of transplantation and the risk of recipient mortality if transmission occurs. In general, for donors who recovered from COVID-19 21 to 90 days prior to donation, the likelihood of transmission via transplantation of non-lung organs is low, and a positive NAAT is not thought to reflect active/transmissible virus [<a href="#rid2">2</a>]. For those who more recently recovered or who have no clear history of COVID-19, the risk for transmission appears to be low. There are increasing reports of transplantation of non-lung organs from donors with recent SARS-CoV-2 infection that do not lead to viral transmission and have good short-term patient and graft outcomes. Long-term outcomes are not well characterized. </p><p>Similarly, for donors who have been exposed but test negative, the safety of donation is not known. In all cases, consultation with an infectious disease expert can help with test interpretation and risk-benefit analysis [<a href="#rid13">13</a>]. The OPTN has provided a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fmedia%2Fkkhnlwah%2Fsars-cov-2-summary-of-evidence.pdf&amp;token=D%2B8S%2FHQSJZll79beJzjMyercN6kW%2BMYt%2FUs7tUiTInXnmqgdk%2Bk0T1hnjMLWHXPMZsH0FN43K3hUK7HtlOIM8ReNPKhTj70TSl82mxBqCx4%3D&amp;TOPIC_ID=127582" target="_blank">summary of the evidence</a> to help guide decision-making.</p><p class="headingAnchor" id="H76404855"><span class="h2">Candidate screening</span><span class="headingEndMark"> — </span>Potential organ transplant recipients should be screened for COVID-19 by history, chest imaging, and microbiologic testing prior to transplantation, according to local center guidance and policies. </p><p>Candidates with active COVID-19 should generally be deferred for transplantation.</p><p>For patients with active COVID-19 and patients who screen positive, the optimal deferral period is not known. The AST suggests waiting until all symptoms have resolved and at least one NAAT for SARS-CoV-2 has been negative [<a href="#rid12">12,15</a>]. Some centers prefer to have two negative NAATs for enhanced sensitivity. However, as with any transplantation, the risk of transplantation must be balanced with the risk of not transplanting a patient with acute or recent COVID-19.</p><p class="headingAnchor" id="H179789547"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H2253614056"><span class="h2">General measures</span><span class="headingEndMark"> — </span>Preventive measures for organ transplant recipients are similar to those defined for the general population. However, we continue to advise vaccinated transplant recipients to maintain personal measures to minimize exposure to SARS-CoV-2 (eg, masking, distancing, avoiding crowds when possible) because early data suggest that vaccine response is suboptimal and that newer omicron variants are more readily transmitted, regardless of vaccination status. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Prevention'</a>.)</p><p>One additional consideration is that solid organ transplant recipients who have COVID-19 may shed greater amounts of virus for longer durations than nonimmunosuppressed patients [<a href="#rid16">16,17</a>]. Thus, a longer duration of isolation and/or testing may be needed to document viral clearance to help reduce the likelihood of spreading the infection to others [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the home setting'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Discontinuation of precautions'</a>.) </p><p>Centers for Disease Control and Prevention (CDC) guidance on the duration of isolation and quarantine for immunocompromised patients can be found <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Fduration-isolation.html&amp;token=0WE0xJ5Cv73iqJ2EioqljSeZwmrd5we07g09SnuVG%2FFtI4uNa69wY0ivF7mmoP6CQMCmi%2BuDr1tpANqqqERkFqq2bzgAtWxfaq53PlklC%2B0%3D&amp;TOPIC_ID=127582" target="_blank">here</a>. </p><p class="headingAnchor" id="H3094260226"><span class="h2">Vaccination</span><span class="headingEndMark"> — </span>All solid organ transplant recipients should undergo COVID-19 vaccination, unless contraindicated (eg, hypersensitivity to the vaccine or its components). Although the immunogenicity and efficacy of COVID-19 vaccines are lower in solid organ transplant recipients than the general population [<a href="#rid19">19,20</a>], the benefit from vaccination outweighs risk. Solid organ transplant recipients should continue to adhere to protective measures (such as masking and social distancing) despite vaccination, based upon data suggesting a suboptimal immune response among transplant recipients [<a href="#rid21">21-25</a>] and studies suggesting lower efficacy against severe disease [<a href="#rid26">26,27</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing</strong> – The ideal timing of vaccination in the posttransplantation setting is not known. In all cases, we weigh the likelihood of contracting COVID-19 (based on community prevalence) against the probability of developing a protective immune response to vaccination.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Whenever possible, vaccination should occur prior to transplantation (ideally with completion of a vaccine series a minimum of two weeks prior to transplant).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If vaccination prior to transplantation is not possible, we delay vaccination for at least one month from the time of transplantation and for at least three months after use of T cell-depleting agents (eg, anti-thymocyte globulin) or specific B cell-depletion agents (eg, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who are transplanted between vaccine doses, we delay the second dose until at least one month after transplantation (if induction did not include a T or B cell-depleting agent) and for three months when a T or B cell-depleting agent was used for induction.</p><p></p><p class="bulletIndent1">These recommendations are consistent with expert guidance from International Society for Heart and Lung Transplantation (ISHLT) [<a href="#rid28">28</a>]; the American Society of Transplantation (AST) also recommends vaccinating at least two weeks before transplantation but does not specify whether vaccination should be delayed when T or B cell-depleting agents are used [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and interval </strong>– The dose and interval of COVID-19 vaccination in transplant recipients is the same as that for other individuals with moderate to severe immunocompromising conditions and is detailed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression and vaccine response</strong> – The optimal approach to managing immunosuppression around the time of vaccination is not known, and approaches vary among experts:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For transplant recipients outside of the early posttransplantation period, there are insufficient data to guide modifications of immunosuppression in anticipation of, or preparation for, vaccination, and society guidelines do not recommend routine modification of immunosuppression [<a href="#rid30">30</a>]. However, some experts favor holding the antimetabolite (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil [MMF]) around the time of vaccination to maximize the likelihood of developing protective immunity [<a href="#rid31">31</a>]; there is no specific evidence to guide how best to adjust immunosuppression with respect to timing, duration, or specific medication adjustment. MMF has been associated with a lower odds of positive antibody response to vaccination among solid organ transplant recipients [<a href="#rid19">19,32</a>]. However, in one trial in kidney transplant recipients who did not develop an antibody response after two of three doses of mRNA vaccine, temporary discontinuation of MMF prior to immunization did not improve seroconversion [<a href="#rid33">33</a>]. Although one study of kidney transplant recipients found an association between mammalian (mechanistic) target of rapamycin (mTOR) inhibitor therapy and improved humoral and cellular immune response to a two-dose mRNA vaccine [<a href="#rid34">34</a>], this finding was not confirmed in a larger study [<a href="#rid32">32</a>]. A clinical trial evaluating the effects of immunosuppression reduction on vaccine response is in progress (NCT05060991).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For those receiving B or T cell-depleting therapy for rejection or other indications, we may delay vaccination for one to three months depending on the agent used. Because the impact of depleting therapies, especially with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, may be prolonged, suboptimal responses may still occur even after three months.</p><p></p><p class="bulletIndent1">Available studies have not reported an increased rate of acute allograft rejection with vaccination.</p><p></p><p class="bulletIndent1">Specific details on vaccine administration (eg, intervals between vaccination, lack of need for serologic testing) are similar to those for the general population. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Breakthrough infections after vaccination </strong>– Breakthrough infections among vaccinated solid organ transplant patients, including cases requiring hospitalization and mechanical ventilation, have been reported [<a href="#rid35">35-41</a>]. Although the overall incidence of severe breakthrough infections among vaccinated transplant patients is low, it appears to be greater than that among vaccinated individuals in the general population. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Protection against severe disease or death'</a>.)</p><p></p><p class="headingAnchor" id="H2740350444"><span class="h2">Preexposure prophylaxis</span><span class="headingEndMark"> — </span>There are currently no FDA-approved options for preexposure prophylaxis (PrEP) because most circulating variants are resistant or have reduced susceptibility to these therapies. (See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention", section on 'Monoclonal antibodies ineffective for pre-exposure prophylaxis'</a>.) </p><p class="headingAnchor" id="H4039991157"><span class="h1">ACTIVE COVID-19 IN SOLID ORGAN TRANSPLANT RECIPIENTS</span></p><p class="headingAnchor" id="H3823449141"><span class="h2">Clinical presentation</span></p><p class="headingAnchor" id="H2918126467"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Clinical features of COVID-19 among solid organ transplant recipients are variable and similar to those in immunocompetent patients. However, fever appears to be less common, possibly as a consequence of the effects of immunosuppressive therapy on the systemic inflammatory response [<a href="#rid42">42-46</a>]. As an example, in two case series of solid organ transplant recipients in New York City, fever was a presenting symptom in only 58 to 70 percent [<a href="#rid43">43,44</a>]. Lymphopenia is also common and may be more profound than in nontransplant patients with COVID-19 [<a href="#rid44">44,46</a>].</p><p class="headingAnchor" id="H1070085401"><span class="h3">Severity of illness</span><span class="headingEndMark"> — </span>The incidence of COVID-19 infection is similar or slightly higher among solid organ transplant recipients compared with the general population. Hospitalization rates are also higher among solid organ transplant recipients [<a href="#rid47">47,48</a>]. However, among those who require hospitalization, the risk for mortality appears to be similar to that for the general population when adjusted for comorbidities [<a href="#rid48">48-54</a>]. Severity of disease among solid organ transplant recipients appears to be attenuated with the Omicron variant compared with prior variants [<a href="#rid55">55</a>].</p><p>Risk factors for severe COVID-19 are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Risk factors for severe illness'</a>.)</p><p class="headingAnchor" id="H1946109989"><span class="h2">Effect of immunosuppression</span><span class="headingEndMark"> — </span>The impact of immunosuppression in the solid organ transplant population on COVID-19 disease severity remains unclear. The pathogenesis of COVID-19 appears to represent an interplay between direct virally mediated injury and the associated host response, with experimental data suggesting that a dysregulated and hyperintense immune response may mediate more severe disease [<a href="#rid56">56</a>]. Since immunosuppressive agents modulate several aspects of the host immune response, the severity of COVID-19 could potentially be affected by the type, combinations, and intensity of immunosuppression. As an example, certain immunosuppressive medications can either directly (eg, lymphocyte-depleting antibodies) or indirectly (eg, antimetabolites) cause lymphopenia, which is a reported risk factor for severe COVID-19 illness [<a href="#rid57">57,58</a>]. Specific agents that have been independently associated with decreased immune responses to vaccines (eg, mammalian [mechanistic] target of rapamycin [mTOR] inhibitors, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>) could theoretically impair the ability to develop an adequate immune response to natural infection. Conversely, some experimental data suggest that mTOR inhibitors may have some biological activity against SARS-CoV-2 [<a href="#rid59">59</a>]. Additional studies are required to determine the impact of specific immunosuppressive agents on the course of COVID-19.</p><p class="headingAnchor" id="H693200979"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Criteria for testing for COVID-19 in solid organ transplant recipients are similar to those for the general population. </p><p>Like other immunocompromised patients, solid organ transplant recipients may "shed" virus for longer periods than the general population after an acute episode of COVID-19. Thus, the detection of RNA and/or antigen ("shedding") may not necessarily indicate active or transmissible disease. Clinical evaluation, exposure history, and serial testing may be helpful in distinguishing between active or transmissible infection versus prolonged, nontransmissible shedding. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Persistent or recurrent positive NAAT during convalescence'</a> and  <a class="medical medical_review" href="/z/d/html/129312.html" rel="external">"COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID")"</a>.)</p><p>Specific testing and screening methods are discussed in the table  (<a class="graphic graphic_table graphicRef128419" href="/z/d/graphic/128419.html" rel="external">table 1</a>) and separately. (See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis", section on 'Clinical suspicion'</a> and  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p class="headingAnchor" id="H1082250663"><span class="h2">Management</span></p><p class="headingAnchor" id="H2314206902"><span class="h3">General considerations</span><span class="headingEndMark"> — </span>The approach to the management of acute COVID-19 in solid organ transplant recipients is similar to that for nontransplant patients; however, because of their immunosuppressed status, the threshold to treat early and mild infections and provide post- or preexposure prophylaxis is lower  (<a class="graphic graphic_algorithm graphicRef139859" href="/z/d/graphic/139859.html" rel="external">algorithm 1</a>). In addition, careful attention should be paid to drug-drug interactions. (See <a class="local">'Drug-drug interactions'</a> below.)</p><p>These issues are discussed in more detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127488.html" rel="external">"COVID-19: Clinical manifestations and diagnosis in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127419.html" rel="external">"COVID-19: Management of the intubated adult"</a>.)</p><p></p><p class="headingAnchor" id="H984275705"><span class="h3">Adjusting immunosuppression</span><span class="headingEndMark"> — </span>Adjustments to the immunosuppressive regimen are necessarily individualized, based upon disease severity, the specific regimen used, type of organ transplanted, time posttransplant, and the risk of acute allograft rejection [<a href="#rid43">43,46,49,57,58,60-62</a>].</p><p>Although the optimal approach is not defined, we usually reduce immunosuppression in patients with moderate to severe COVID-19 (eg, those requiring hospitalization):</p><p class="bulletIndent1"><span class="glyph">●</span>As a first step, we often reduce or hold the antimetabolite (eg, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/sodium), particularly for patients with lymphopenia (eg, absolute lymphocyte count &lt;700 cells/mL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We generally continue the calcineurin inhibitor (CNI) because CNIs inhibit interleukin (IL) 6 and IL-1 pathways; these cytokines may contribute to the development of the severe, dysregulated immune response seen in some patients with severe COVID-19.</p><p></p><p>In all cases the decision to reduce immunosuppression must be carefully weighed against the risk for acute rejection, particularly in transplant recipients who generally require high levels of maintenance immunosuppression (eg, lung or heart recipients). Data supporting our approach and any other are limited to observational studies [<a href="#rid43">43,44,46,49,63,64</a>]. In addition, this approach does not preclude the use of high-dose glucocorticoids and other immunomodulators for severe COVID-19 infection.</p><p>There are also concerns that COVID-19 itself may increase the risk for acute rejection and that an overly intense inflammatory host immune response might contribute to overall disease severity. Thus, attenuating the immune response by maintaining low-dose immunosuppression could theoretically be beneficial. In addition, experimental data suggest that certain immunosuppressive agents such as mTOR inhibitors may have some biological activity against SARS-CoV-2 [<a href="#rid59">59</a>]. Additional studies are required to confirm these findings.</p><p>Additional guidance on adjusting immunosuppression in transplant recipients with active infection can be found in the following topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">"Kidney transplantation in adults: Maintenance immunosuppressive therapy", section on 'Patients who develop infection'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation", section on 'Monitoring and adjusting maintenance therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127537.html" rel="external">"COVID-19: Evaluation and management of cardiac disease in adults", section on 'Cardiac transplantation'</a>.)</p><p></p><p>Recommendations from specific medical societies are listed separately. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H4207961903"><span class="h3">Drug-drug interactions</span><span class="headingEndMark"> — </span>Several new antiviral medications are being evaluated or have already been approved for treatment of COVID-19 (see  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Specific treatments'</a>). Clinicians should be aware that these medications have potential drug-drug interactions with immunosuppressive medications that are commonly used among solid organ transplant recipients (such as CNIs)  (<a class="graphic graphic_table graphicRef110436" href="/z/d/graphic/110436.html" rel="external">table 2</a>). If these immunosuppressive agents are continued during COVID-19 infection, their blood levels should be frequently monitored [<a href="#rid65">65</a>]. </p><p>As an example, <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> has been authorized for emergency use by the United States Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults and children at high risk for progression to severe disease. Nirmatrelvir-ritonavir is an inhibitor of CYP3A and may increase plasma concentrations of drugs that are primarily metabolized by CYP3A. Concomitant use with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> should be avoided, and blood levels of other immunosuppressive agents (such as CNIs) should be monitored. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Nirmatrelvir-ritonavir as preferred therapy'</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting", section on 'Therapies of limited or uncertain benefit'</a>.)</p><p class="headingAnchor" id="H1488667397"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a>.)</p><p class="headingAnchor" id="H3576531963"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2071537298"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Challenges for organ transplantation</strong> – COVID-19 poses challenges for individual solid organ transplant candidates and recipients and the process of organ transplantation. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of transmission</strong> – Donor-derived SARS-CoV-2 infection has been reported through lung transplantation but not via non-lung transplantation. (See <a class="local">'Potential for donor-derived infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening before transplantation</strong> – Because of the risk for progression to severe disease and the potential for transmitting SARS-CoV-2 to health care providers, solid organ donor and transplant candidates should generally be screened for COVID-19 by history, chest imaging, and microbiologic testing. (See <a class="local">'Pretransplantation screening'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttransplant risk</strong> – Posttransplantation, solid organ transplant recipients may be at increased risk for acquisition of infection, progression to symptomatic infection, and/or development of more severe COVID-19. (See <a class="local">'Posttransplantation risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of COVID-19 in solid organ transplant recipients are variable and generally similar to those observed in nonimmunocompromised patients. However, fever appears to be less common. (See <a class="local">'Clinical presentation'</a> above and <a class="local">'Severity of illness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The approach to diagnosis is similar to that for the general population. Because signs and symptoms of COVID-19 may be subtle in transplant recipients and disease progression can be rapid, some clinicians have a lower threshold for evaluating and testing transplant recipients. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management approach</strong> – The approach to management (eg, use of antivirals, supportive care) is also similar to that for the general population. Careful attention should be paid to potential drug-drug interactions and effects on the immunosuppressive regimen. (See <a class="local">'General considerations'</a> above and <a class="local">'Drug-drug interactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjusting immunosuppression</strong> – Adjustments to the immunosuppressive regimen are necessarily individualized, based upon disease severity, the specific regimen used, type of organ transplant, time posttransplant, and the risk of acute allograft rejection. Some organ transplant recipients recover without reduction in immunosuppression, which carries the risk of rejection and immune reconstitution. Conversely, continued immunosuppression may enhance the risk of uncontrolled infection. (See <a class="local">'Adjusting immunosuppression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccination</strong> – All transplant recipients are eligible for vaccination with an extended dose vaccine series, unless contraindicated (eg, hypersensitivity to the vaccine or its components). The ideal timing in the posttransplantation setting is uncertain. Because early data suggest that vaccine response is suboptimal, we continue to advise that vaccinated transplant recipients maintain personal measures to minimize exposure to SARS-CoV-2 (eg, masking, distancing, avoiding crowds when possible). (See <a class="local">'Vaccination'</a> above and <a class="local">'General measures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preexposure prophylaxis</strong> – Preexposure prophylaxis (PrEP) with monoclonal antibodies (eg, tixagevimab plus cilgavimab) was authorized for use as PrEP in patients (aged ≥12 years) with moderate to severe immunosuppression. However, most circulating variants are resistant or have reduced susceptibility to these therapies and are not available for routine use. (See <a class="local">'Preexposure prophylaxis'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kute VB, Fleetwood VA, Meshram HS, et al. Use of Organs from SARS-CoV-2 Infected Donors: Is It Safe? A Contemporary Review. Curr Transplant Rep 2021; 8:281.</a></li><li><a class="nounderline abstract_t">Koval CE, Poggio ED, Lin YC, et al. Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases. Am J Transplant 2021; 21:3743.</a></li><li><a class="nounderline abstract_t">Neidlinger NA, Smith JA, D'Alessandro AM, et al. Organ recovery from deceased donors with prior COVID-19: A case series. Transpl Infect Dis 2021; 23:e13503.</a></li><li><a class="nounderline abstract_t">Bock MJ, Vaughn GR, Chau P, et al. Organ transplantation using COVID-19-positive deceased donors. Am J Transplant 2022; 22:2203.</a></li><li><a class="nounderline abstract_t">Schold JD, Koval CE, Wee A, et al. Utilization and outcomes of deceased donor SARS-CoV-2-positive organs for solid organ transplantation in the United States. Am J Transplant 2022; 22:2217.</a></li><li><a class="nounderline abstract_t">Dhand A, Okumura K, Nabors C, Nishida S. Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database. Transpl Infect Dis 2023; 25:e13925.</a></li><li><a class="nounderline abstract_t">Koval CE, Eltemamy M, Poggio ED, et al. Comparative outcomes for over 100 deceased donor kidney transplants from SARS-CoV-2 positive donors: A single-center experience. Am J Transplant 2022; 22:2903.</a></li><li><a class="nounderline abstract_t">Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA 2020; 323:1843.</a></li><li><a class="nounderline abstract_t">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497.</a></li><li><a class="nounderline abstract_t">Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfus Med Rev 2020; 34:75.</a></li><li class="breakAll">Organ retrieval for transplantation in the COVID-19 era. American Society of Transplant Surgeons. https://asts.org/advocacy/covid-19-resources/asts-covid-19-strike-force/asts-covid-19-strike-force-organ-retrieval-guidance#.Xqb1BGhKiUl (Accessed on April 26, 2020).</li><li class="breakAll">American Society for Transplantation. Information for transplant professionals and community members regarding 2019 novel coronavirus. https://www.myast.org/sites/default/files/1COVID19%20FAQ%20Tx%20Centers%2004.15.2020.pdf (Accessed on April 18, 2020).</li><li class="breakAll">https://optn.transplant.hrsa.gov/media/kkhnlwah/sars-cov-2-summary-of-evidence.pdf (Accessed on December 03, 2021).</li><li class="breakAll">https://optn.transplant.hrsa.gov/media/4576/policy_notice_lunglowerrespiratorytesting_20210426.pdf (Accessed on December 03, 2021).</li><li class="breakAll">COVID-19: FAQs for Organ Transplantation. American Society of Transplantation. Updated January 29, 2022. (Available at: https://www.myast.org/sites/default/files/2022_Jan_29.%20Clean_FAQ_COVIDUpdates.pdf).</li><li><a class="nounderline abstract_t">Man Z, Jing Z, Huibo S, et al. Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia. Am J Transplant 2020; 20:2626.</a></li><li><a class="nounderline abstract_t">Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. Eur Urol 2020; 77:748.</a></li><li class="breakAll">https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html (Accessed on January 21, 2022).</li><li><a class="nounderline abstract_t">Li J, Ayada I, Wang Y, et al. Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis. Transplantation 2022; 106:2068.</a></li><li><a class="nounderline abstract_t">Phadke VK, Scanlon N, Jordan SC, Rouphael NG. Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients. Curr Transplant Rep 2021; 8:127.</a></li><li><a class="nounderline abstract_t">Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients. JAMA 2021; 325:1784.</a></li><li><a class="nounderline abstract_t">Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA 2021; 325:2204.</a></li><li><a class="nounderline abstract_t">Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant 2021; 21:2719.</a></li><li class="breakAll">https://www.myast.org/statement-covid-19-vaccination-solid-organ-transplant-recipients (Accessed on May 25, 2021).</li><li><a class="nounderline abstract_t">Shostak Y, Shafran N, Heching M, et al. Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine. Lancet Respir Med 2021; 9:e52.</a></li><li><a class="nounderline abstract_t">Heeger PS, Larsen CP, Segev DL. Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients. Sci Immunol 2021; 6.</a></li><li><a class="nounderline abstract_t">Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep 2021; 70:1553.</a></li><li class="breakAll">SARS-CoV-2 Vaccination in Heart and Lung Transplantation: Recommendations from the ISHLT COVID-19 Task Force https://ishlt.org/ishlt/media/Documents/COVID19_Vaccine-Recommendations_3-15-2021.pdf (Accessed on March 19, 2021).</li><li class="breakAll">American Society of Transplantation COVID-19 Vaccination Guidance
. http://www.myast.org/sites/default/files/AST-COVID-PtVaccine-3.18.21-final.pdf (Accessed on March 21, 2021).</li><li class="breakAll">https://www.myast.org/sites/default/files/2021%2005%2018%20COVID19%20VACCINE%20FAQS-final%20update.pdf (Accessed on July 01, 2021).</li><li><a class="nounderline abstract_t">Kantauskaite M, Müller L, Kolb T, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant 2022; 22:634.</a></li><li><a class="nounderline abstract_t">Bae S, Alejo JL, Chiang TPY, et al. mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients. Am J Transplant 2022; 22:3137.</a></li><li><a class="nounderline abstract_t">Kho MML, Messchendorp AL, Frölke SC, et al. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial. Lancet Infect Dis 2023; 23:307.</a></li><li><a class="nounderline abstract_t">Netti GS, Infante B, Troise D, et al. mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients. Am J Transplant 2022; 22:1475.</a></li><li><a class="nounderline abstract_t">Tsapepas D, Paget K, Mohan S, et al. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Am J Kidney Dis 2021; 78:314.</a></li><li><a class="nounderline abstract_t">Malinis M, Cohen E, Azar MM. Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. Am J Transplant 2021; 21:2916.</a></li><li><a class="nounderline abstract_t">Anjan S, Natori Y, Fernandez Betances AA, et al. Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida. Transplantation 2021; 105:e139.</a></li><li><a class="nounderline abstract_t">Qin CX, Moore LW, Anjan S, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation 2021; 105:e265.</a></li><li><a class="nounderline abstract_t">Aslam S, Adler E, Mekeel K, Little SJ. Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients. Transpl Infect Dis 2021; 23:e13705.</a></li><li><a class="nounderline abstract_t">Mehta RB, Silveira FP. COVID-19 after two doses of mRNA vaccines in kidney transplant recipients. Am J Transplant 2021; 21:4102.</a></li><li class="breakAll">https://www.cdc.gov/mmwr/volumes/70/wr/mr7044e3.htm (Accessed on January 21, 2022).</li><li><a class="nounderline abstract_t">Guillen E, Pineiro GJ, Revuelta I, et al. Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation? Am J Transplant 2020; 20:1875.</a></li><li><a class="nounderline abstract_t">Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant 2020; 20:1800.</a></li><li><a class="nounderline abstract_t">Akalin E, Azzi Y, Bartash R, et al. Covid-19 and Kidney Transplantation. N Engl J Med 2020; 382:2475.</a></li><li><a class="nounderline abstract_t">Tschopp J, L'Huillier AG, Mombelli M, et al. First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. Am J Transplant 2020; 20:2876.</a></li><li><a class="nounderline abstract_t">Caillard S, Anglicheau D, Matignon M, et al. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int 2020; 98:1549.</a></li><li><a class="nounderline abstract_t">Overvad M, Koch A, Jespersen B, et al. Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study. Am J Transplant 2022; 22:2627.</a></li><li><a class="nounderline abstract_t">Hadi YB, Naqvi SFZ, Kupec JT, et al. Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network. Transplantation 2021; 105:1365.</a></li><li><a class="nounderline abstract_t">Kates OS, Haydel BM, Florman SS, et al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study. Clin Infect Dis 2021; 73:e4090.</a></li><li><a class="nounderline abstract_t">Bossini N, Alberici F, Delbarba E, et al. Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. Am J Transplant 2020; 20:3019.</a></li><li><a class="nounderline abstract_t">Favà A, Cucchiari D, Montero N, et al. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. Am J Transplant 2020; 20:3030.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Bhalla A, Azhar A, et al. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States. Am J Transplant 2020; 20:3061.</a></li><li><a class="nounderline abstract_t">Avery RK. COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now? Transplantation 2021; 105:56.</a></li><li><a class="nounderline abstract_t">Avery RK, Chiang TP, Marr KA, et al. Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. Am J Transplant 2021; 21:2498.</a></li><li><a class="nounderline abstract_t">Cochran W, Shah P, Barker L, et al. COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. Transplantation 2022; 106:e346.</a></li><li><a class="nounderline abstract_t">Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620.</a></li><li><a class="nounderline abstract_t">Requião-Moura LR, Modelli de Andrade LG, de Sandes-Freitas TV, et al. The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19. Transplantation 2022; 106:e441.</a></li><li><a class="nounderline abstract_t">Gérard AO, Barbosa S, Anglicheau D, et al. Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients. Transplantation 2022; 106:2063.</a></li><li><a class="nounderline abstract_t">Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34:327.</a></li><li><a class="nounderline abstract_t">Latif F, Farr MA, Clerkin KJ, et al. Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019. JAMA Cardiol 2020; 5:1165.</a></li><li><a class="nounderline abstract_t">Yi SG, Rogers AW, Saharia A, et al. Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. Transplantation 2020; 104:2208.</a></li><li><a class="nounderline abstract_t">Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. Am J Transplant 2020; 20:1819.</a></li><li><a class="nounderline abstract_t">Zhong Z, Zhang Q, Xia H, et al. Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Am J Transplant 2020; 20:1916.</a></li><li><a class="nounderline abstract_t">Banerjee D, Popoola J, Shah S, et al. COVID-19 infection in kidney transplant recipients. Kidney Int 2020; 97:1076.</a></li><li><a class="nounderline abstract_t">Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions. Ther Drug Monit 2020; 42:360.</a></li></ol></div><div id="topicVersionRevision">Topic 127582 Version 43.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34722116" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Use of Organs from SARS-CoV-2 Infected Donors: Is It Safe? A Contemporary Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34254424" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Early success transplanting kidneys from donors with new SARS-CoV-2 RNA positivity: A report of 10 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33174324" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Organ recovery from deceased donors with prior COVID-19: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35822320" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Organ transplantation using COVID-19-positive deceased donors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35730252" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Utilization and outcomes of deceased donor SARS-CoV-2-positive organs for solid organ transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35942924" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Solid organ transplantation from COVID positive donors in the United States: Analysis of United Network for Organ Sharing database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36176236" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparative outcomes for over 100 deceased donor kidney transplants from SARS-CoV-2 positive donors: A single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32159775" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Detection of SARS-CoV-2 in Different Types of Clinical Specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31986264" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32107119" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Coronavirus Disease 2019: Coronaviruses and Blood Safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32400931" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Viral shedding prolongation in a kidney transplant patient with COVID-19 pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317180" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317180" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35761439" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Factors Associated With COVID-19 Vaccine Response in Transplant Recipients: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33688459" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33720292" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33950155" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866672" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33866672" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33964244" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34210786" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735426" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735426" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735426" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34735426" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34551181" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35869809" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36354032" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35038362" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34019949" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34101990" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34319928" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Breakthrough COVID-19 Infections After mRNA Vaccination in Solid Organ Transplant Recipients in Miami, Florida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34310531" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34324256" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34331745" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : COVID-19 after two doses of mRNA vaccines in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34331745" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : COVID-19 after two doses of mRNA vaccines in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32198834" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330343" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : COVID-19 in solid organ transplant recipients: Initial report from the US epicenter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32329975" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Covid-19 and Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32412159" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853631" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35801493" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Outcomes following SARS-CoV-2 infection in individuals with and without solid organ transplantation-A Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33988341" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes of COVID-19 in Solid Organ Transplant Recipients: A Propensity-matched Analysis of a Large Research Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766815" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32627319" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32777153" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844546" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33141805" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33284498" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35404880" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32217835" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical and immunological features of severe and moderate coronavirus disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35765133" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35883236" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171193" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32402056" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32496357" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32351040" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : COVID-19 in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282986" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32354637" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : COVID-19 infection in kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32304488" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
